Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis.

What the trial testedas reported · 2,606 people · 2026

Range includes no effect

−0.30−0.62 to +0.01

As reported

difference −0.30, 95% CI −0.62 to 0.01

the abstract, start to end

… fasting plasma glucose, with an SMD of -0.30 (95% CI: -0.62 to 0.01; …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.30−0.62 to 0.01

Diet, exercise & lifestyleGlycemic control

1 / 3